1. Home
  2. SLXN vs XELB Comparison

SLXN vs XELB Comparison

Compare SLXN & XELB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLXN
  • XELB
  • Stock Information
  • Founded
  • SLXN 2008
  • XELB 2011
  • Country
  • SLXN Israel
  • XELB United States
  • Employees
  • SLXN N/A
  • XELB N/A
  • Industry
  • SLXN
  • XELB Multi-Sector Companies
  • Sector
  • SLXN
  • XELB Miscellaneous
  • Exchange
  • SLXN NYSE
  • XELB Nasdaq
  • Market Cap
  • SLXN 6.9M
  • XELB 5.6M
  • IPO Year
  • SLXN N/A
  • XELB N/A
  • Fundamental
  • Price
  • SLXN $0.93
  • XELB $2.53
  • Analyst Decision
  • SLXN Strong Buy
  • XELB
  • Analyst Count
  • SLXN 1
  • XELB 0
  • Target Price
  • SLXN $5.00
  • XELB N/A
  • AVG Volume (30 Days)
  • SLXN 3.6M
  • XELB 222.0K
  • Earning Date
  • SLXN 05-21-2025
  • XELB 05-19-2025
  • Dividend Yield
  • SLXN N/A
  • XELB N/A
  • EPS Growth
  • SLXN N/A
  • XELB N/A
  • EPS
  • SLXN N/A
  • XELB N/A
  • Revenue
  • SLXN N/A
  • XELB $9,337,000.00
  • Revenue This Year
  • SLXN N/A
  • XELB N/A
  • Revenue Next Year
  • SLXN N/A
  • XELB $71.83
  • P/E Ratio
  • SLXN N/A
  • XELB N/A
  • Revenue Growth
  • SLXN N/A
  • XELB N/A
  • 52 Week Low
  • SLXN $0.21
  • XELB $2.02
  • 52 Week High
  • SLXN $13.56
  • XELB $8.49
  • Technical
  • Relative Strength Index (RSI)
  • SLXN N/A
  • XELB 46.66
  • Support Level
  • SLXN N/A
  • XELB $2.12
  • Resistance Level
  • SLXN N/A
  • XELB $4.20
  • Average True Range (ATR)
  • SLXN 0.00
  • XELB 0.39
  • MACD
  • SLXN 0.00
  • XELB 0.04
  • Stochastic Oscillator
  • SLXN 0.00
  • XELB 23.39

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

About XELB Xcel Brands Inc.

Xcel Brands Inc is a media and brand management company. It is engaged in design, merchandising and planning, sourcing and production, licensing, marketing, and brand development. The company offers branded apparel, footwear, accessories, jewelry, home goods, and other consumer products. Its brand portfolio consists of the Isaac Mizrahi, Judith Ripka, H Halston, C Wonder, and the Highline Collective brands. The company licenses its brands to third parties, provides certain design, production, and marketing services, and generates licensing, design, and service fee revenues through contractual arrangements and other agreements.

Share on Social Networks: